GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eckert & Ziegler SE (MIL:1EUZ) » Definitions » Financial Strength

Eckert & Ziegler SE (MIL:1EUZ) Financial Strength : 9 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Eckert & Ziegler SE Financial Strength?

Eckert & Ziegler SE has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Eckert & Ziegler SE shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Eckert & Ziegler SE's Interest Coverage for the quarter that ended in Sep. 2024 was 16.61. Eckert & Ziegler SE's debt to revenue ratio for the quarter that ended in Sep. 2024 was 0.19. As of today, Eckert & Ziegler SE's Altman Z-Score is 4.88.


Competitive Comparison of Eckert & Ziegler SE's Financial Strength

For the Medical Devices subindustry, Eckert & Ziegler SE's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eckert & Ziegler SE's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's Financial Strength distribution charts can be found below:

* The bar in red indicates where Eckert & Ziegler SE's Financial Strength falls into.



Eckert & Ziegler SE Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Eckert & Ziegler SE's Interest Expense for the months ended in Sep. 2024 was €-0.9 Mil. Its Operating Income for the months ended in Sep. 2024 was €15.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €42.7 Mil.

Eckert & Ziegler SE's Interest Coverage for the quarter that ended in Sep. 2024 is

Interest Coverage=-1*Operating Income (Q: Sep. 2024 )/Interest Expense (Q: Sep. 2024 )
=-1*15.364/-0.925
=16.61

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Eckert & Ziegler SE's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(9.221 + 42.7) / 280.452
=0.19

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Eckert & Ziegler SE has a Z-score of 4.88, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 4.88 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eckert & Ziegler SE  (MIL:1EUZ) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Eckert & Ziegler SE has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.


Eckert & Ziegler SE Financial Strength Related Terms

Thank you for viewing the detailed overview of Eckert & Ziegler SE's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Eckert & Ziegler SE Business Description

Address
Robert-Rossle-Street 10, Berlin, BB, DEU, 13125
Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial use. It is predominantly engaged in the business of cancer therapy, industrial radiometry, and nuclear medical imaging. The company's segments are Medical, Isotope Products, and Other. The Isotope Products segment which generates key revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. The Medical segment provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. The Other segment comprises the items of the holding company. Geographically, the company generates a majority of its revenue from Europe and the rest from North America, Asia/Pacific, and other regions.

Eckert & Ziegler SE Headlines

No Headlines